Keyphrases
Hemophilia
97%
Pediatric
85%
Thrombin Generation
69%
Emicizumab
56%
Pediatric Patients
47%
Venous Thromboembolism
33%
B Cells
30%
Activated Protein C
26%
Inherited Thrombophilia
26%
Bleeding
24%
Rare Bleeding Disorders
24%
Thrombosis
23%
Anticoagulant Treatment
23%
T Cells
22%
Severe Haemophilia A
21%
Factor VIII (FVIII)
21%
Gene Therapy
20%
Direct Oral Anticoagulants
19%
FVIII Inhibitors
19%
Recombinant Activated Factor VII (rFVIIa)
19%
Thrombophilia
19%
Pediatric Immune Thrombocytopenia
18%
Bleeding Episodes
18%
Protein C Deficiency
18%
Hemostasis
18%
Splanchnic Vein Thrombosis
17%
Glanzmann Thrombasthenia
17%
Literature Trends
17%
Text Mining
17%
Rivaroxaban
17%
High-level Analysis
17%
NLRP3 Inflammasome
17%
Myopic Choroidal Neovascularization (mCNV)
17%
Hemophilia A Carrier
17%
Thrombocytopenia
17%
Hemophilia B
16%
Immune Thrombocytopenia
15%
FEIBA
15%
Pediatric Population
14%
Haemophilia with Inhibitors
14%
Bleeding Complications
14%
Tertiary Care Hospital
13%
Recurrent Venous Thromboembolism
13%
Etiology
13%
Risk Factors
12%
Clinical Characteristics
12%
Factor VIII Inhibitor
12%
Pediatric Research
11%
Clinical Trials
11%
Murine Model
11%
Medicine and Dentistry
Pediatrics
100%
Haemophilia A
85%
Thrombin
58%
Emicizumab
47%
Bleeding
42%
Hemostat
39%
Patient with Hemophilia
35%
Pediatrics Patient
35%
Blood Stasis
27%
Phlebothrombosis
26%
Bleeding Disorder
26%
Activated Protein C
25%
Thrombosis
24%
Thrombophilia
23%
Anticoagulant Therapy
22%
Gene Therapy
20%
Venous Thromboembolism
20%
Activated Prothrombin Complex
19%
Diseases
19%
Ex Vivo
18%
Glanzmann's Thrombasthenia
17%
Choroidal Neovascularization
17%
NLRP3 Inflammasome
17%
Systematic Review
17%
Idiopathic Thrombocytopenic Purpura
17%
Haemophilia B
17%
Recurrent Disease
16%
Immunological Tolerance
15%
Cancer
15%
Substitution Therapy
14%
Prospective Study
14%
Thrombocytopenia
13%
Malignant Neoplasm
13%
Blood Clotting Factor 8 Inhibitor
11%
Clinical Trial
11%
Platelet
10%
Direct Oral Anticoagulant
10%
Neonate
10%
Thromboelastography
10%
Interleukin-1
10%
Microglia
10%
Ciclonicate
10%
Meta-Analysis
10%
Blood Clotting Factor
10%
Vasculotropin
9%
Inflammatory Cell
9%
Protein C Deficiency
9%
Bleeding Diathesis
9%
T Cell
8%
Splenic Infarction
8%
